Moderna stock price ticked up to $95.85 after Goldman Sachs reiterated its 'Buy' rating. Analyst models suggest upside potential toward $110 over the next 12 months if revenue diversification accelerates. While we acknowledge the potential of MRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . Moderna burned through $3.49 billion of cash over the last year. With $5.13 billion of cash on its balance sheet, the company has around 18 months of runway left (assuming its $741 million of debt isn’t due right away). Moderna stock price is currently trading around $95.40, reflecting a mild rebound of 1.2% today after recent biotech sector weakness. Analysts are watching pipeline updates, especially mRNA infectious disease programs, as possible catalysts for further upward momentum.
